

HOUSE RESEARCH

Bill Summary

FILE NUMBER: H.F. 1199
Version: As introduced

DATE: March 14, 2013

Authors: Mahoney and others

Subject: Small business investment credit modifications

Analyst: Nina Manzi (651) 296-5204; Joel Michael (joel.michael@house.mn); and Anita Neumann

This publication can be made available in alternative formats upon request. Please call 651-296-6753 (voice); or the Minnesota State Relay Service at 1-800-627-3529 (TTY) for assistance. Summaries are also available on our website at: www.house.mn/hrd/.

Overview

Modifies the angel investment credit by:

- increasing the number of years in which a business may have been in operation from 10 to 20 for businesses engaged in developing drugs that require FDA approval;
- prohibiting investments from qualifying for the credit if the business made a public stock offering before receiving the investment;
- prohibiting businesses receiving creditable investment from making a public stock offering or selling the business within six months after the investment was made; and
- allowing contact information on the businesses receiving the credit to be disclosed to the public.

Section

1 Angel credit; definitions. Provides a new definition of “liquidation event” as a conversion of a qualified investment to cash, cash and other considerations, or any other form of debt or equity interest.

Effective date: Effective for businesses certified after June 30, 2013.

2 Angel credit; qualifying small business. Makes several changes in the requirements that a small business must satisfy for the business and investments in it to qualify under the angel investment credit:

- Extends the number of years in which a business may have been in operation from

Section

ten to 20 in the case of businesses engaged in researching, developing, or producing drugs that require U.S. Food and Drug Administration approval;

- Prohibits the business from having its securities trade on a public stock exchange prior to the investment being made and within 180 days of the date of the investment; and
- Prohibits the business from having a liquidation event, defined in section 1, within 180 days of the date the investment qualifying for the credit was made.

Effective date: The change related to businesses engaged in developing drugs that require FDA approval is effective the day following final enactment; the other changes are effective for businesses certified after June 30, 2013.

- 3** **Angel credit, permitted disclosure.** Modifies the exemption from the Data Practices Act for disclosure of information on the businesses that receive investments qualifying for the angel credit. Under present law, only the name of the qualified business may be disclosed. This section would allow the mailing address, telephone number, e-mail address, contact person's name, and industry type to also be disclosed.

Effective date: Effective the day following final enactment.